Additionally, miR-192 suppresses tumor growth in brain cancers, targeting RAB2A in glioblastoma multiforme [23], ZEB2 in glioma [22], and DHFR in medulloblastoma [24]. This evidence concerns the gene RAB2A and central nervous system cancer.